share_log

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

2022年9月15日的重要生物技术催化剂-当天结束摘要
Benzinga Real-time News ·  2022/09/15 18:48
Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7 to $46.29 on day volume of 15.14 million shares, closed regular trading session at $45.94.
辉瑞公司(纽约证券交易所股票代码:PFE)宣布了关键的第三阶段试验的正面结果,该试验评估了其正在研究的五价脑膜炎双球菌疫苗(MenABCWY)在10至25岁健康人群中的安全性、耐受性和免疫原性。试验满足了所有主要和次要终端。辉瑞股价在45.7美元至46.29美元的区间内交易,当日成交量为1,514万股,常规交易时段收于45.94美元。
Alnylam (NASDAQ: ALNY) and Regeneron (NASDAQ: REGN) announced preliminary Phase 1 data supporting the clinical advancement of ALN-HSD, an investigational RNAi therapeutic targeting HSD17B13 in development for the treatment of nonalcoholic steatohepatitis (NASH). Alnylam shares traded in a range of $202.6 to...
阿尔尼拉姆(纳斯达克:ALNY)和再生纳斯达克代码:REGN)宣布了支持ALN-...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发